Search Results - Elizabeth J Kelly

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination by Deidre Wilkins, Anastasia A Aksyuk, Alexey Ruzin, Kevin M Tuffy, Tina Green, Rebecca Greway, Brittany Fikes, Cyrille J Bonhomme, Mark T Esser, Elizabeth J Kelly

    Published in Clinical & Translational Immunology (2022-01-01)
    Get full text
    Article


  2. 2

    Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection by Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly

    Published in Frontiers in Immunology (2023-10-01)
    Get full text
    Article


  3. 3

    Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity by Ann Marie Stanley, Anastasia A. Aksyuk, Deidre Wilkins, Justin A. Green, Dongmei Lan, Kathryn Shoemaker, Hong-Van Tieu, Hong-Van Tieu, Magdalena E. Sobieszczyk, Ann R. Falsey, Ann R. Falsey, Elizabeth J. Kelly

    Published in Frontiers in Immunology (2024-05-01)
    Get full text
    Article


  4. 4

    Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring by Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L. Roe, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. Kelly

    Published in Microbiology Spectrum (2022-10-01)
    Get full text
    Article


  5. 5

    Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) by Gustavo H. Kijak, Bahar Ahani, Douglas Arbetter, Fernando Chuecos, Vancheswaran Gopalakrishnan, Jagadish Beloor, Tyler Brady, Amy Nguyen, Tiffany L. Roe, Nicolette Schuko, Tianhui Zhang, F. D. Richard Hobbs, Francisco Padilla, Elizabeth J. Kelly, Hugh Montgomery, Katie Streicher

    Published in Infectious Diseases and Therapy (2023-11-01)
    Get full text
    Article


  6. 6

    Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12 by Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, Elena Galvani, Shannon Burke, Ankita Varshine, Raymond Rothstein, Kevin Schifferli, Noel R. Monks, Johann Foloppe, Nathalie Silvestre, Eric Quemeneur, Christelle Demeusoit, Patricia Kleinpeter, Puja Sapra, Carl Barrett, Scott A. Hammond, Elizabeth J. Kelly, Jason Laliberte, Nicholas M. Durham, Michael Oberst, Maria A.S. Broggi

    Published in Molecular Therapy: Oncology (2024-03-01)
    Get full text
    Article


  7. 7

    Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials by Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana

    Published in Nature Communications (2024-04-01)
    Get full text
    Article


  8. 8

    Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials by Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana

    Published in Nature Communications (2023-07-01)
    Get full text
    Article


  9. 9

    Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months by Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck Jr., Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, and Ian Hirsch, on behalf of the AstraZeneca AZD1222 Clinical Study Group

    Published in The Journal of Clinical Investigation (2022-09-01)
    Get full text
    Article


  10. 10

    Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults by Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale

    Published in Human Vaccines & Immunotherapeutics (2024-12-01)
    Get full text
    Article


  11. 11

    Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated by Jill Maaske, Stephanie Sproule, Ann R. Falsey, Ann R. Falsey, Magdalena E. Sobieszczyk, Anne F. Luetkemeyer, Grant C. Paulsen, Grant C. Paulsen, Sharon A. Riddler, Merlin L. Robb, Charlotte-Paige Rolle, Beverly E. Sha, Tina Tong, Bahar Ahani, Anastasia A. Aksyuk, Himanshu Bansal, Timothy Egan, Brett Jepson, Marcelino Padilla, Nirmeshkumar Patel, Kathryn Shoemaker, Ann Marie Stanley, Phillip A. Swanson, Deidre Wilkins, Tonya Villafana, Justin A. Green, Elizabeth J. Kelly

    Published in Frontiers in Immunology (2023-01-01)
    Get full text
    Article


  12. 12

    The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus by Annefleur C. Langedijk, Bram Vrancken, Robert Jan Lebbink, Deidre Wilkins, Elizabeth J. Kelly, Eugenio Baraldi, Abiel Homero Mascareñas de Los Santos, Daria M. Danilenko, Eun Hwa Choi, María Angélica Palomino, Hsin Chi, Christian Keller, Robert Cohen, Jesse Papenburg, Jeffrey Pernica, Anne Greenough, Peter Richmond, Federico Martinón-Torres, Terho Heikkinen, Renato T. Stein, Mitsuaki Hosoya, Marta C. Nunes, Charl Verwey, Anouk Evers, Leyla Kragten-Tabatabaie, Marc A. Suchard, Sergei L. Kosakovsky Pond, Chiara Poletto, Vittoria Colizza, Philippe Lemey, Louis J. Bont, on behalf of the INFORM-RSV Study Group

    Published in Nature Communications (2024-04-01)
    Get full text
    Article


  13. 13

    Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine by David Benkeser, Youyi Fong, Holly E. Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, Ann Marie Stanley, Jill Maaske, Tonya Villafana, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Victor Ayala, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Lindsay N. Carpp, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Corey Hoffman, Ann R. Falsey, Magdalena Sobieszczyk, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, on behalf of the AstraZeneca AZD1222 Clinical Study Group, the Immune Assays Team, the United States Government (USG)/CoVPN Biostatistics Team

    Published in npj Vaccines (2023-03-01)
    Get full text
    Article


  14. 14

    Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil by Sue Ann Costa Clemens, MD, PhD, Sagida Bibi, PhD, Natalie G. Marchevsky, MSc, Parvinder K. Aley, PhD, Federica Cappuccini, PhD, Sophie A. Davies, BSc, Isabela Gonzalez, PhD, Sarah C. Kelly, MSc, Yama F. Mujadidi, MSc, Eveline Pipolo Milan, MD, PhD, Alexandre V. Schwarzbold, PhD, Eduardo Sprinz, MD, DSc, Merryn Voysey, DPhil, Lily Y. Weckx, MD, PhD, Daniel Wright, DPhil, Himanshu Bansal, MS, Maria A.S. Bergagård, MSc, Abby J. Isaacs, MS, Elizabeth J. Kelly, PhD, Dongmei Lan, MS, Shethah Morgan, PhD, Nirmal Kumar Shankar, BAMS, Kathryn Shoemaker, MS, Tonya L. Villafana, PhD, Teresa Lambe, PhD, Justin A. Green, MD, PhD, Andrew J. Pollard, FMedSci

    Get full text
    Article


Search Tools: